Patterns of prescription of antipsychotics in Qatar.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
03
2020
accepted:
25
10
2020
entrez:
9
11
2020
pubmed:
10
11
2020
medline:
5
1
2021
Statut:
epublish
Résumé
Even though all guidelines recommend generally against antipsychotic polypharmacy, antipsychotic polypharmacy appears to be a very common practice across the globe. This study aimed to examine the prescription patterns of antipsychotics in Qatar, in comparison with the international guidelines, and to scrutinize the sociodemographic and clinical features associated with antipsychotic polypharmacy. All the medical records of all the inpatients and outpatients treated by antipsychotics at the Department of Psychiatry-Hamad Medical Corporation (HMC) in Doha, Qatar (between October 2012 and April 2014) were retrospectively analyzed. We retrieved the available sociodemographic data, psychiatric features, and details on the medication history. Our sample consisted of 537 individuals on antipsychotics (2/3 were male; mean age 33.8±10.2 years), prescribed for a psychotic disorder in 57%, a mood disorder in 9.3%, and various other diagnoses in 33.7%. About 55.9% received one antipsychotic, 29.6% received two antipsychotics, and 14.5% received more than two antipsychotics. Polypharmacy was associated with younger age (p = 0.025), being single (p<0.001), the diagnosis of a psychotic disorder (p<0.001), and previous admissions to psychiatry (p<0.001). Antipsychotic polypharmacy appears to be quite common in Qatar, as it is the case in many other countries, in contrast with most international recommendations. Studies are needed to explore the reasons behind this disparity.
Identifiants
pubmed: 33166337
doi: 10.1371/journal.pone.0241986
pii: PONE-D-20-08216
pmc: PMC7652328
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0241986Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Psychopharmacol. 2015 Apr;29(4):353-62
pubmed: 25516373
Int Clin Psychopharmacol. 2014 Sep;29(5):288-95
pubmed: 24323200
Br J Psychiatry. 2012 Dec;201(6):481-5
pubmed: 22955007
Age Ageing. 2011 May;40(3):368-75
pubmed: 21429950
J Clin Psychiatry. 2003 Jun;64(6):663-7
pubmed: 12823080
Asian J Psychiatr. 2018 Mar;33:113-120
pubmed: 29574303
Psychiatry Clin Neurosci. 2006 Dec;60(6):778-9
pubmed: 17109719
Clin Psychopharmacol Neurosci. 2014 Aug;12(2):128-36
pubmed: 25191503
Int Rev Psychiatry. 2019 Aug - Sep;31(5-6):441-459
pubmed: 31225767
N Z Med J. 2018 Aug 17;131(1480):61-67
pubmed: 30116066
Psychiatry Clin Neurosci. 2018 Aug;72(8):572-579
pubmed: 29761577
Clin Pract Epidemiol Ment Health. 2017 Aug 11;13:92-103
pubmed: 29081826
J Clin Psychiatry. 2002 Feb;63(2):93-4
pubmed: 11874226
Asian J Psychiatr. 2019 Jan;39:93-97
pubmed: 30597443
Can J Psychiatry. 2017 Sep;62(9):604-616
pubmed: 28703015
Ir J Psychol Med. 2019 Dec;36(4):279-291
pubmed: 30477599
J R Coll Physicians Edinb. 2018 Sep;48(3):225-232
pubmed: 30191910
World Psychiatry. 2017 Feb;16(1):77-89
pubmed: 28127934
Curr Med Chem. 2004 Feb;11(3):313-27
pubmed: 14965234
Psychiatr Serv. 2014 Feb 1;65(2):186-92
pubmed: 24233347
Yonago Acta Med. 2018 Jun 18;61(2):91-102
pubmed: 29946215
Ther Adv Psychopharmacol. 2017 Mar;7(3):103-111
pubmed: 28348730
Neuropsychiatr Dis Treat. 2015 Apr 01;11:915-24
pubmed: 25897227
Acta Psychiatr Scand. 2002 Nov;106(5):323-30
pubmed: 12366465
Schizophr Res. 2012 Jun;138(1):18-28
pubmed: 22534420
Schizophr Res. 2019 Jul;209:50-57
pubmed: 31182319
Br J Psychiatry. 2006 Feb;188:122-7
pubmed: 16449697
Psychiatr Serv. 2017 Jun 1;68(6):579-586
pubmed: 28196460
JAMA Psychiatry. 2019 May 1;76(5):499-507
pubmed: 30785608